查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863371

基因編輯技術市場按技術平台、應用、最終用戶、給藥方法和疾病分類－2025-2032年全球預測

Gene Editing Technologies Market by Technology Platform, Application, End User, Delivery Method, Disease Indication - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，基因編輯技術市場將成長至 152.8 億美元，複合年成長率為 13.04%。

主要市場統計數據
基準年 2024 57.3億美元
預計年份：2025年 64.8億美元
預測年份：2032年 152.8億美元
複合年成長率 (%) 13.04%

本文簡要概述了現代基因編輯技術，重點介紹了技術進步、應用研究進展以及各領域相關人員的戰略考慮。

過去十年，基因編輯技術已從一項前景看好的實驗室技術發展成為重塑生物醫學研究、農業科學和工業生物技術的基礎工具。核酸酶設計、遞送系統和編輯精度的進步使研究人員能夠以前所未有的解析度分析生物系統，而臨床項目和轉化流程也穩步推進，從概念驗證走向治療應用。因此，各領域的相關人員都在調整其投資組合、投資重點和合作模式，以充分挖掘這些平台的科學和商業性潛力。

近期在基因編輯化學、遞送方法和監管措施方面的技術突破如何重塑創新路徑和商業性合作

基因編輯技術正經歷著一場變革性的轉變，這主要得益於精準化學技術的進步、模組化平台架構的建構以及連接髮現與應用的成熟生態系統。近期的技術里程碑凸顯了鹼基編輯和先導編輯方法的重要性，這些方法減少了對雙鏈機制的依賴，提高了特異性並拓寬了治療範圍。同時，TALEN、ZFN 和Meganucleases傳統平台技術的持續改進，在那些對客製化標靶和智慧財產權要求較高的領域，仍能提供獨特的優勢。

評估不斷變化的關稅政策將如何重塑參與基因編輯研究和生產的組織的供應鏈、籌資策略和跨境業務營運選擇。

貿易和關稅政策的變化會對研究投入、供應鏈以及基因編輯創新成果轉化為實用化解決方案的經濟效益產生連鎖反應。影響試劑、定序耗材、病毒載體組成或專用設備的關稅會在籌資策略中造成摩擦點，迫使各機構重新評估採購管道、管理庫存並實現供應商多元化。因此，實驗室和製造商可能會修改供應商合約和物流安排，以維持營運的連續性和研究效率。

透過細分市場分析，將平台功能、交付選項、應用領域和最終用戶需求連結起來，從而指導策略優先排序和產品定位。

細分市場層面的差異化是理解技術能力與應用需求和最終使用者需求交會點的核心。在平台層面，CRISPR、巨型核酸酶、TALEN 和 ZFN 之間的差異對於標靶選擇、智慧財產權策略和生產流程至關重要。在 CRISPR 內部，鹼基編輯、Cas9 和先導編輯等​​子平台各有優劣。鹼基編輯減少了對雙鏈的依賴，並細分為腺嘌呤鹼基編輯和胞嘧啶鹼基編輯模式，分別針對不同的突變場景。同時，先導編輯擴展了無需供體模板即可實現的精確編輯範圍。

區域比較趨勢突顯了美洲、歐洲、中東、非洲和亞太地區在轉化能力、監管方法和商業機會方面的差異。

區域趨勢持續對基因編輯研究、開發和應用的軌跡產生重大影響。在美洲，轉化研究、創業投資和臨床基礎設施的優勢相結合，為加速治療計畫和擴大生產能力創造了有利條件。該地區的生態系統還擁有密集的合約研究組織和專業服務公司網路，能夠支持從藥物發現到臨床檢驗的快速迭代。

獨特的平台、合作結構和製造能力，定義了基因編輯生態系統中的競爭優勢和夥伴關係策略。

基因編輯領域的競爭格局是由專有平台、合作聯盟和垂直整合策略共同塑造的。擁有差異化編輯方法或遞送平台的機構通常會利用授權合約、共同開發夥伴關係和策略採購來擴大其業務範圍，同時保持其核心技術優勢。同時，服務供應商和受託研究機構透過提供臨床前測試、載體生產和監管支援方面的專業知識，在降低研發風險方面發揮關鍵作用。

領導者可以採取哪些具體的策略和營運步驟，來協調平台選擇、交付最佳化、供應鏈韌性和相關人員參與，從而建立永續的優勢。

領導者應採取務實的投資組合策略，平衡平台開發、特定應用投資和營運韌性。首先，應優先考慮與組織優勢相符的技術路線。擁有深厚機制專業知識的組織可以投資改進起始基因和基礎基因編輯，而擁有成熟病毒載體技術的組織則可以專注於最佳化嗜性並提高生產效率。同時，應透過有針對性的夥伴關係以及在研發計畫早期整合轉換終點，加強遞送技術和安全性評估能力。

我們採用透明的混合調查方法研究設計，結合專家訪談、文獻綜合和情境檢驗，來檢驗我們對平台、應用程式和營運的推論。

這些研究成果的依據是系統性文獻綜述、專家訪談以及對技術和應用領域發展軌跡的結構化分析。研究重點包括與轉化科學家、臨床開發負責人、生產專家和商業負責人進行對話，以獲取有關技術限制、監管參與和營運重點的第一手資訊。輔助資料包括同行評審論文、監管指導文件和技術白皮書，以幫助評估平台功能和交付方式。

將科學、營運和政策方面的必要性整合起來，組織必須協調一致，才能將基因編輯技術的進步轉化為切實可行的治療、農業和工業成果。

基因編輯技術正處於一個關鍵的轉折點，技術進步、遞送方式創新以及不斷變化的監管和政策環境在此交匯融合，既創造了新的機遇，也帶來了切實的營運挑戰。精準編輯化學的進步和多樣化的遞送方式拓展了基因編輯技術的應用範圍，從治療項目到農業和工業用途，無所不包。同時，地緣政治因素、供應鏈脆弱性以及公眾對安全性和透明度的日益成長的期望，都要求各組織採取整合策略，將卓越的科學技術與前瞻性的營運能力相結合。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將機器學習演算法和 CRISPR 系統結合以提高標靶特異性的進展
  • 加速基因治療中用於單鹼基校正的鹼基編輯平台的商業化
  • 擴展基於 CRISPR 的診斷技術，以實現感染疾病的快速現場診斷
  • 開發用於控制蚊子族群的基因驅動技術，以對抗撒哈拉以南非洲的瘧疾傳播
  • 表觀基因編輯工具能夠對疾病相關基因表現進行可逆調控。
  • 人類生殖細胞編輯法規結構的演化對研究資金籌措和公眾接受度的影響
  • 生技Start-Ups與製藥公司合作，推動CAR-T基因編輯治療方法的研發
  • 利用高保真度的enCas12a突變體最大限度地減少農業基因組編輯中的脫靶突變

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按技術平台分類的基因編輯技術市場

  • CRISPR
    • 基礎編輯
      • 腺嘌呤鹼基編輯
      • 胞嘧啶鹼基編輯
    • Cas9
    • Prime Edit
  • Meganucleases
  • TALEN
  • ZFN

第9章 按應用分類的基因編輯技術市場

  • 農業
    • 農作物
    • 家畜
  • 工業的
    • 生質燃料
    • 生質塑膠
  • 研究工具
    • 偵測
    • 細胞株工程
    • 圖書館篩檢
  • 治療用途
    • Ex Vivo
      • 免疫療法
      • 幹細胞療法
    • In Vivo
      • 生殖系基因編輯
      • 體細胞基因編輯

第10章 基因編輯技術市場（依最終用戶分類）

  • 生物製藥公司
    • 大型生物製藥公司
    • 中小型生物製藥公司
  • 受託研究機構
    • 臨床
    • 臨床前
  • 醫療中心和醫院
    • 診所
    • 醫院
  • 研究機構和學術中心
    • 學術研究
    • 政府實驗室

第11章 基因編輯技術市場（依給藥方式分類）

  • 非病毒性
    • 電穿孔
    • 脂質奈米顆粒
    • 顯微注射
  • 病毒性的
    • 腺結合病毒
    • 慢病毒
    • 逆轉錄病毒

第12章 依疾病分類的基因編輯技術市場

  • 感染疾病
  • 腫瘤學
    • 骨髓惡性腫瘤
    • 固態腫瘤
  • 罕見遺傳疾病
    • 囊腫纖維化
    • 鐮狀細胞性貧血症

第13章 基因編輯技術市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 基因編輯技術市場（依群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國基因編輯技術市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Merck KGaA
    • Roche Holding AG
    • Agilent Technologies, Inc.
    • Sartorius AG
    • Bio-Rad Laboratories, Inc.
    • QIAGEN NV
    • Lonza Group AG
    • Takara Bio Inc.
Product Code: MRR-2E76C3E47FBE

The Gene Editing Technologies Market is projected to grow by USD 15.28 billion at a CAGR of 13.04% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.73 billion
Estimated Year [2025] USD 6.48 billion
Forecast Year [2032] USD 15.28 billion
CAGR (%) 13.04%

A succinct orientation to contemporary gene editing that outlines technological advances, translational momentum, and strategic considerations for stakeholders across sectors

The past decade has seen gene editing evolve from a promising laboratory technique into a foundational tool reshaping biomedical research, agricultural science, and industrial biotechnology. Advances in nuclease design, delivery systems, and editing precision have enabled researchers to interrogate biological systems with unprecedented resolution, while clinical programs and translational pipelines have moved increasingly from conceptual demonstration toward therapeutic application. As a result, stakeholders across disciplines are recalibrating portfolios, investment priorities, and collaborative models to capture the scientific and commercial potential of these platforms.

This introduction synthesizes the current landscape by focusing on the converging technical advances and ecosystem dynamics that matter to executives and R&D leaders. It highlights the interplay between platform innovation and downstream application, the growing importance of delivery and safety considerations, and the shifting expectations around regulatory dialogues and public acceptance. By foregrounding these themes, the narrative sets a pragmatic foundation for subsequent sections that address structural shifts, policy impacts, segmentation intelligence, regional patterns, and actionable recommendations for organizations seeking to navigate the gene editing frontier.

How recent technical breakthroughs in editing chemistry, delivery modalities, and regulatory engagement are recalibrating innovation pathways and commercial collaborations

Gene editing is undergoing transformative shifts driven by refinements in precision chemistry, modular platform architectures, and a maturing ecosystem that links discovery to application. Recent technical milestones have emphasized base editing and prime editing modalities that reduce reliance on double-strand break mechanisms, thereby improving specificity and broadening the set of treatable targets. At the same time, incremental improvements in traditional platforms such as TALEN, ZFN, and meganuclease technologies continue to offer niche advantages where bespoke targeting or intellectual property considerations prevail.

Concurrently, the landscape is changing as delivery innovations-ranging from lipid nanoparticle formulations to viral vector engineering-reshape how therapies reach target tissues and how agricultural or industrial edits are deployed. This nexus of platform sophistication and delivery robustness is catalyzing new partnerships between biotechnology developers, contract research providers, and advanced manufacturing specialists. Moreover, ethical and regulatory discourse has intensified, prompting more proactive engagement between developers and regulators to define acceptable risk thresholds and clinical endpoints. Together, these shifts are creating an environment where iterative technical improvement and pragmatic governance combine to accelerate translational pathways and broaden the practical reach of gene editing applications.

Assessing how evolving tariff policies reshape supply chains, procurement strategies, and cross-border operational choices for entities engaged in gene editing research and production

Policy changes in trade and tariff regimes can have cascading effects on research inputs, supply chains, and the economics of translating gene editing innovations into deployable solutions. Tariffs that affect reagents, sequencing consumables, viral vector components, or specialized equipment create friction points in procurement strategies, forcing organizations to reassess sourcing, inventory, and vendor diversification. In turn, laboratories and manufacturers may alter supplier contracts and logistics arrangements to preserve continuity of operations and maintain research throughput.

Beyond procurement, tariffs can influence strategic decisions such as location of preclinical manufacturing, choices about in-house versus outsourced capabilities, and the structuring of cross-border collaborations. Academic centers, contract research organizations, and biopharmaceutical developers may respond by consolidating key operations in tariff-favored jurisdictions or by deepening partnerships with regional suppliers. Importantly, these adjustments often lead to increased emphasis on supply chain visibility and risk management, with teams investing in scenario planning and buffer strategies. In aggregate, tariff dynamics reshape the operational calculus for organizations engaging in gene editing R&D and production, underscoring the need for adaptable sourcing frameworks and proactive commercial planning.

Segment-focused analysis linking platform characteristics, delivery choices, application domains, and end-user needs to inform strategic prioritization and product positioning

Segment-level differentiation is central to understanding where technical capabilities intersect with application demand and end-user needs. On the platform side, distinctions among CRISPR, meganuclease, TALEN, and ZFN are consequential for target selection, intellectual property strategy, and manufacturing workflows. Within CRISPR, sub-platforms such as Base Editing, Cas9, and Prime Editing offer distinct trade-offs: Base Editing reduces double-strand break reliance and is subdivided into Adenine Base Editing and Cytosine Base Editing modalities that address different mutational contexts, while Prime Editing expands the range of precise edits that can be achieved without donor templates.

Application segmentation further clarifies use cases, spanning Agricultural pursuits with crops and livestock applications, Industrial uses focused on biofuels and bioplastics, Research Tools encompassing assays, cell line engineering, and library screening, and Therapeutic development that separates Ex Vivo approaches-such as immunotherapy and stem cell therapy-from In Vivo strategies, which include germline and somatic editing. End users vary accordingly; large and small biopharmaceutical companies, clinical and preclinical contract research organizations, clinics and hospitals within medical centers, and academic research groups and government laboratories each demand different data packages, regulatory support, and commercialization roadmaps. Delivery method choices between Nonviral techniques like electroporation, lipid nanoparticle formulations, and microinjection, and Viral vectors such as adeno-associated virus, lentivirus, and retrovirus, influence development timelines, scalability, and safety profiles. Disease indication prioritization, including infectious diseases, oncology with its hematological and solid tumor subcategories, and rare genetic disorders such as cystic fibrosis and sickle cell disease, shapes clinical endpoints and patient recruitment strategies. Together, these segmentation vectors provide a multidimensional framework for aligning technology selection, development pathways, and commercial tactics with specific organizational goals.

Comparative regional dynamics that highlight differentiated translational capacity, regulatory approaches, and operational opportunities across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to exert a strong influence on the trajectory of gene editing research, development, and deployment. In the Americas, strengths in translational research, venture capital formation, and clinical infrastructure create favorable conditions for accelerating therapeutic programs and scaling manufacturing capabilities. This regional ecosystem also hosts a dense network of contract research providers and specialized service firms that support rapid iteration from discovery to clinical validation.

The Europe, Middle East & Africa region presents a heterogeneous landscape in which robust academic ecosystems and well-developed regulatory frameworks coexist with jurisdictions that are still building advanced manufacturing and clinical trial capacity. Policy variability across countries requires careful navigation, yet the region's emphasis on ethical oversight and patient safety frequently leads to close regulatory engagement and high standards for clinical evidence. In the Asia-Pacific region, expanding biotechnology talent pools, growing manufacturing capacity, and proactive industrial strategies have led to intensified activity across both therapeutic and agricultural applications. Cross-border partnerships, regional supply chains, and investments in next-generation facilities characterize this area, creating options for organizations seeking operational redundancy and cost-effective production. These regional patterns underscore the necessity of tailoring commercialization strategies, regulatory approaches, and partner selection to the specific strengths and constraints of each geography.

How proprietary platforms, alliance structures, and manufacturing capabilities define competitive advantage and partnership strategies across the gene editing ecosystem

Competitive dynamics in the gene editing landscape are shaped by a combination of proprietary platforms, collaborative alliances, and vertical integration strategies. Organizations that control differentiated editing modalities or delivery platforms frequently leverage licensing arrangements, co-development partnerships, and strategic sourcing to extend their reach while retaining core technological advantages. Concurrently, service providers and contract research organizations play a pivotal role in de-risking development pathways by offering specialized capabilities in preclinical testing, vector manufacturing, and regulatory support.

Intellectual property management, manufacturing scale-up, and clinical trial design are recurring battlegrounds where firms seek durable advantages. Companies with integrated manufacturing capabilities can accelerate timelines and exert greater control over quality, whereas those focused on platform refinement may rely on partnerships to commercialize downstream applications. Additionally, cross-sector collaborations that combine academic discovery with commercial development continue to be a fertile source of innovation, particularly when they address translational bottlenecks such as delivery, immunogenicity mitigation, and long-term safety monitoring. For decision-makers, understanding how prospective partners or rivals configure these capabilities is essential when evaluating alliance fit, outsourcing decisions, and in-licensing opportunities.

Practical strategic and operational steps leaders can implement to align platform choices, delivery optimization, supply chain resilience, and stakeholder engagement for durable advantage

Leaders should adopt a pragmatic portfolio approach that balances platform development with application-focused investments and operational resilience. Begin by prioritizing technology routes that align with institutional strengths: organizations with deep mechanistic expertise may invest in prime editing or base editing refinement, while those with established viral vector competencies might focus on optimizing tropism and manufacturing throughput. Simultaneously, strengthen delivery and safety assessment capabilities through targeted partnerships and by integrating translational endpoints early in development planning.

Operationally, diversify supply chains and engage in scenario planning to mitigate tariff-related and geopolitical risks. Contractual arrangements that incorporate dual sourcing, regional manufacturing options, and inventory buffering will reduce exposure to procurement disruptions. On the commercial front, cultivate relationships with clinical networks, payers, and patient advocacy groups to ensure that development programs reflect realistic clinical pathways and adoption considerations. Finally, invest in regulatory engagement and ethical communications to build trust with stakeholders and streamline approvals. By executing on these interconnected actions, institutions can better position themselves to translate technical advances into durable clinical, agricultural, or industrial outcomes.

A transparent mixed-method research design that integrates expert interviews, literature synthesis, and scenario testing to validate platform, application, and operational inferences

The research underpinning these insights combined systematic literature review, expert interviews, and structured analysis of technology and application trajectories. Primary engagements included conversations with translational scientists, clinical development leads, manufacturing experts, and commercial strategists to capture first-hand perspectives on technical constraints, regulatory interactions, and operational priorities. Secondary sources consisted of peer-reviewed publications, regulatory guidance documents, and technical white papers that informed assessments of platform capabilities and delivery approaches.

To ensure rigor, the methodology emphasized triangulation across data types and stakeholders, cross-checking claims about platform performance against empirical evidence from preclinical and early clinical studies, and validating operational inferences through practitioner feedback. Scenario analysis was used to explore the implications of policy shifts and supply chain disruptions, while segmentation logic was constructed to reflect the practical decision nodes that organizations face when selecting platforms, applications, delivery methods, and end-user targets. This mixed-method approach produced a structured evidence base that supports actionable recommendations while maintaining transparency about limits and assumptions.

Synthesis of the scientific, operational, and policy imperatives that organizations must reconcile to translate gene editing advances into tangible therapeutic, agricultural, and industrial outcomes

Gene editing stands at a pivotal juncture where technical progress, delivery innovation, and evolving regulatory and policy environments converge to create new opportunities and real operational challenges. Advances in precision editing chemistries and diversified delivery methods have expanded the range of feasible applications from therapeutic programs to agricultural and industrial uses. At the same time, geopolitical factors, supply chain fragility, and heightened expectations for safety and transparency demand that organizations adopt integrated strategies that combine scientific excellence with operational foresight.

Moving forward, sustained progress will require coordinated investment in delivery science, robust engagement with regulatory and ethical stakeholders, and flexible commercial strategies that reflect regional differences and end-user needs. Organizations that successfully navigate this landscape will be those that marry deep technical capabilities with pragmatic supply chain and partnership choices, and who prioritize the translational steps needed to move from laboratory promise to real-world impact. The conclusion underscores the importance of aligning internal capabilities with external realities to realize the full potential of gene editing technologies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing integration of machine learning algorithms with CRISPR systems to enhance target specificity
  • 5.2. Accelerating commercialization of base editing platforms for single nucleotide correction in genetic therapies
  • 5.3. Expansion of CRISPR-based diagnostics enabling rapid point-of-care detection of infectious diseases
  • 5.4. Development of gene drives for mosquito population control to combat malaria transmission in sub-Saharan Africa
  • 5.5. Emergence of epigenome editing tools for reversible regulation of disease-related gene expression profiles
  • 5.6. Evolving regulatory frameworks for human germline editing influencing research funding and public acceptance
  • 5.7. Collaborations between biotech startups and pharmaceutical companies to advance CAR-T gene editing therapeutics
  • 5.8. Adoption of high-fidelity enCas12a variants to minimize off-target mutations in agricultural genome engineering

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Gene Editing Technologies Market, by Technology Platform

  • 8.1. CRISPR
    • 8.1.1. Base Editing
      • 8.1.1.1. Adenine Base Editing
      • 8.1.1.2. Cytosine Base Editing
    • 8.1.2. Cas9
    • 8.1.3. Prime Editing
  • 8.2. Meganuclease
  • 8.3. TALEN
  • 8.4. ZFN

9. Gene Editing Technologies Market, by Application

  • 9.1. Agricultural
    • 9.1.1. Crops
    • 9.1.2. Livestock
  • 9.2. Industrial
    • 9.2.1. Biofuels
    • 9.2.2. Bioplastics
  • 9.3. Research Tools
    • 9.3.1. Assays
    • 9.3.2. Cell Line Engineering
    • 9.3.3. Library Screening
  • 9.4. Therapeutic
    • 9.4.1. Ex Vivo
      • 9.4.1.1. Immunotherapy
      • 9.4.1.2. Stem Cell Therapy
    • 9.4.2. In Vivo
      • 9.4.2.1. Germline Gene Editing
      • 9.4.2.2. Somatic Gene Editing

10. Gene Editing Technologies Market, by End User

  • 10.1. Biopharmaceutical Companies
    • 10.1.1. Large Biopharma
    • 10.1.2. Small And Medium Biopharma
  • 10.2. Contract Research Organizations
    • 10.2.1. Clinical
    • 10.2.2. Preclinical
  • 10.3. Medical Centers And Hospitals
    • 10.3.1. Clinics
    • 10.3.2. Hospitals
  • 10.4. Research Institutes And Academic Centers
    • 10.4.1. Academic Research
    • 10.4.2. Government Laboratories

11. Gene Editing Technologies Market, by Delivery Method

  • 11.1. Nonviral
    • 11.1.1. Electroporation
    • 11.1.2. Lipid Nanoparticle
    • 11.1.3. Microinjection
  • 11.2. Viral
    • 11.2.1. Adeno Associated Virus
    • 11.2.2. Lentivirus
    • 11.2.3. Retrovirus

12. Gene Editing Technologies Market, by Disease Indication

  • 12.1. Infectious Diseases
  • 12.2. Oncology
    • 12.2.1. Hematological Malignancies
    • 12.2.2. Solid Tumors
  • 12.3. Rare Genetic Disorders
    • 12.3.1. Cystic Fibrosis
    • 12.3.2. Sickle Cell Disease

13. Gene Editing Technologies Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Gene Editing Technologies Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Gene Editing Technologies Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Thermo Fisher Scientific Inc.
    • 16.3.2. Danaher Corporation
    • 16.3.3. Merck KGaA
    • 16.3.4. Roche Holding AG
    • 16.3.5. Agilent Technologies, Inc.
    • 16.3.6. Sartorius AG
    • 16.3.7. Bio-Rad Laboratories, Inc.
    • 16.3.8. QIAGEN N.V.
    • 16.3.9. Lonza Group AG
    • 16.3.10. Takara Bio Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GENE EDITING TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GENE EDITING TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GENE EDITING TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GENE EDITING TECHNOLOGIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CRISPR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENINE BASE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CYTOSINE BASE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CAS9, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEGANUCLEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY TALEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ZFN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY AGRICULTURAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CROPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY INDUSTRIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPLASTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH TOOLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIBRARY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GERMLINE GENE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SOMATIC GENE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LARGE BIOPHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LARGE BIOPHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LARGE BIOPHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LARGE BIOPHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LARGE BIOPHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LARGE BIOPHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SMALL AND MEDIUM BIOPHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SMALL AND MEDIUM BIOPHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SMALL AND MEDIUM BIOPHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SMALL AND MEDIUM BIOPHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SMALL AND MEDIUM BIOPHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY SMALL AND MEDIUM BIOPHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRECLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MEDICAL CENTERS AND HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ACADEMIC RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ACADEMIC RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ACADEMIC RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ACADEMIC RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GOVERNMENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GOVERNMENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GOVERNMENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GOVERNMENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GOVERNMENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY GOVERNMENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY VIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL GENE EDITING TECHNOLOGIES MARKET SIZE, BY ADENO ASSOCIATED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL GENE EDITING TEC